Major depressive disorder (MDD) remains one of the leading causes of disability worldwide, with many patients failing to achieve adequate symptom control despite multiple available antidepressants. Positive topline results from Definium Therapeutics' Phase 3 EMERGE trial (NCT06941844) suggest that a novel psychedelic-based therapy could represent a significant advance in the treatment landscape.

What is DT120?

DT120 is an investigational orally disintegrating tablet (ODT) containing lysergide (LSD) administered as a single 100 μg dose under medical supervision. Unlike conventional antidepressants that require daily dosing for weeks before meaningful benefit is observed, DT120 is designed to provide rapid and sustained antidepressant effects following a one-time treatment session.

About the EMERGE Phase 3 Study

EMERGE is the first of two pivotal Phase 3 studies evaluating DT120 in adults with major depressive disorder. The trial enrolled 149 adults aged 18–74 years with MDD and was a 12-week double-blind, single-administration study (DT120 vs. placebo) with a 40-week extension. The primary endpoint was the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) at Week 6.

Key Findings

The study successfully met its primary endpoint as well as all key secondary endpoints.

Highlights include:

• 8.1-point placebo-adjusted improvement in MADRS score at Week 6 (p < 0.0001)
• 7.3-point placebo-adjusted improvement maintained at Week 12 (p < 0.0001)
• Clinical improvement observed as early as Day 2, with robust symptom reduction evident during the first week
• Approximately 35% of patients achieved treatment response, and 24% reached remission by Week 6, substantially outperforming placebo.

Safety Profile

DT120 demonstrated a favourable safety profile:

• Around 99% of treatment-emergent adverse events were mild to moderate
• No serious treatment-related adverse events were reported
• No increase in suicidal ideation or behaviour was observed
• Most patients completed the monitored treatment session and were discharged within several hours of dosing.

Concerns about double blinding

In a conventional drug trial, neither the patient nor the investigator knows who received the active drug. With LSD, however, this is inherently difficult because the psychoactive effects are obvious.

Participants receiving 100 µg DT120 typically experience many or all of the following:

• altered perception,
• changes in thinking,
• emotional effects,
• mild physiological changes.

Someone receiving placebo generally experiences none of these. As a result, many participants can correctly guess their treatment assignment. Investigators observing patients during the dosing session may also infer it. This phenomenon is called functional unblinding

If patients realize they received the active drug, they may:

• expect improvement (expectancy bias),
• report lower depression scores,
• engage more positively during follow-up assessments.

Likewise, investigators who suspect a participant received DT120 may unintentionally influence clinician-rated scales such as MADRS.

Since the primary endpoint in EMERGE is based on the Montgomery–Åsberg Depression Rating Scale (MADRS), critics argue that expectancy could inflate the apparent treatment effect.

Summary

The magnitude of antidepressant effect reported in EMERGE is notable within the current MDD treatment landscape. Analysts have described the observed efficacy as among the strongest reported in late-stage depression studies, while maintaining an acceptable safety profile under supervised administration. If confirmed in the second pivotal Phase 3 trial (ASCEND), DT120 could become the first FDA-approved LSD-based therapy for major depressive disorder.

Sources:

(1) Definium Therapeutics. (2026, June 22). Definium Therapeutics announces positive topline results from Phase 3 Emerge study of DT120 orally disintegrating tablet (ODT) in major depressive disorder. Morningstar. https://www.morningstar.com/news/business-wire/20260622572802/definium-therapeutics-announces-positive-topline-results-from-phase-3-emerge-study-of-dt120-orally-disintegrating-tablet-odt-in-major-depressive-disorder

(2) ClinicalTrials.gov. (2026, June 29). A Phase 3 trial of DT120 for major depressive disorder (Emerge) (ClinicalTrials.gov Identifier: NCT06941844). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT06941844